ARID1A基因突变与胃癌顺铂耐药的研究进展  

Progress on ARID1A gene mutation and cisplatin resistance in gastric cancer

作　　者：郑振鲁(综述) 高小玲(审校) ZHENG Zhenlu;GAO Xiaoling(School of Public Health,Gansu University of Chinese Medicine,Lanzhou,Gansu 730000,China;Center of Clinical Laboratory,Hainan General Hospital,Haikou,Hainan 570100,China)

机构地区：[1]甘肃中医药大学公共卫生学院,甘肃兰州730000 [2]海南省人民医院医学检验中心,海南海口570100

出　　处：《国际检验医学杂志》2024年第21期2662-2667,2674,共7页International Journal of Laboratory Medicine

基　　金：国家自然科学基金项目(81830372)。

摘　　要：胃癌在世界范围内具有很高的发病率和病死率,尤其是在东亚地区。化疗抵抗或化疗耐药仍然是影响胃癌患者预后的一个重要问题。AT丰富结合域1A(ARID1A)基因是染色质重塑复合物中的重要成员,其突变在胃癌中较为常见,并与患者的临床表现以及化疗反应密切相关。ARID1A基因的缺失或突变可能导致胃癌细胞对铂类化疗药物的耐药性增加。该文对ARID1A基因的生物学作用,顺铂耐药中DNA损伤修复及代谢重塑的改变以及ARID1A基因参与胃癌化疗耐药中的可能机制进行以下综述。Gastric cancer has high mortality and case fatality rate worldwide,especially in East Asia.Chemoresistance or chemotherapeutic resistance remains an important issue affecting the prognosis of gastric cancer patients.Mutations in the AT-rich interactive domain 1A(ARID1A)gene,an important member of the chromatin remodeling complex,are common in gastric cancer and are closely related to the clinical manifestations of patients as well as the response to chemotherapy.Deletion or mutation of the ARID1A gene may lead to increased resistance of gastric cancer cells to platinum-based chemotherapeutic agents.In this paper,the biological role of ARID1A gene,the alteration of DNA damage repair and metabolic remodeling in cisplatin resistance,and the possible mechanism of ARID1A gene involved in chemoresistance in gastric cancer are reviewed.

关 键 词：胃癌 AT丰富结合域1A基因 DNA损伤修复 代谢重塑 化疗耐药 

分 类 号：R735.2[医药卫生—肿瘤]